# Testopel ® vs. Generic Testosterone Pellets.

> **NCT04523480** · PHASE3 · COMPLETED · sponsor: **University of Miami** · enrollment: 75 (actual)

## Conditions studied

- Hypogonadism

## Interventions

- **DRUG:** Testopel 75mg Drug Implant
- **DRUG:** Testopel 100mg Drug Implant
- **DRUG:** Testopel 200mg Drug Implant

## Key facts

- **NCT ID:** NCT04523480
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-12
- **Primary completion:** 2022-12-20
- **Final completion:** 2022-12-20
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2023-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04523480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04523480, "Testopel ® vs. Generic Testosterone Pellets.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04523480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*